---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-216632"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:39:21.121628+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics settles shareholder derivative lawsuit; $590K in fees, governance reforms

## Summary
- Mootness fee of $175,000 paid to resolve certain director compensation claims; company denies wrongdoing.
- Proposed settlement filed Aug 20, 2024; includes corporate governance reforms and up to $415,000 in attorney fees.
- Reforms cap director compensation at 65th percentile of peer group and require value-based equity grants and annual consultant review.
- Court approval required; settlement hearing scheduled for Oct 28, 2024.
- Company agrees to maintain reforms for five years.

## SEC filing metadata
- accession: 0001193125-24-216632
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312524216632/0001193125-24-216632-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312524216632/d836605d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-216632
- JSON: https://secwatch.observer/filing/0001193125-24-216632.json
- Plain text: https://secwatch.observer/filing/0001193125-24-216632.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.